Upadacitinib Immunosuppression and Latent TB Treatment Requirement
Yes, a patient with a positive interferon-gamma release assay (IGRA) absolutely requires latent TB treatment before initiating upadacitinib. The FDA label explicitly mandates that "patients with latent TB should be treated with standard antimycobacterial therapy before initiating RINVOQ" 1.
Degree of Immunosuppression
Upadacitinib is a highly immunosuppressive JAK-1 inhibitor that carries significant infection risk comparable to anti-TNF biologics:
- Serious and sometimes fatal infections have been reported, including tuberculosis, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis 1
- JAK inhibitors (including upadacitinib) confer geographically variable TB risk, with higher rates in intermediate/high-burden countries 2
- The risk of serious infections increases with higher doses (30 mg showed higher rates than 15 mg) 1
- TB and opportunistic infections were observed during JAK inhibitor therapy, with higher rates at increased doses and in older patients 3
Mandatory Pre-Treatment TB Screening and Management
Screening Requirements
The FDA label is unequivocal: "Evaluate and test patients for latent and active tuberculosis (TB) infection prior to administration of RINVOQ" 1. This should include:
- IGRA testing (preferred over tuberculin skin test where available) 4
- Chest X-ray to exclude active TB 4
- Clinical history including TB exposure, residence in endemic areas, and risk factors 4, 1
Treatment Protocol for Positive IGRA
If IGRA is positive:
- Rule out active TB first with chest X-ray and clinical evaluation 1
- Initiate standard antimycobacterial therapy for latent TB before starting upadacitinib 1
- Ideally complete at least 4 weeks of TB prophylaxis before initiating immunosuppression 5
- Do not start upadacitinib if active TB is present 1
Special Considerations
The FDA label also states: "Consider anti-TB therapy prior to initiation of RINVOQ in patients with previously untreated latent TB or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection" 1.
Risk factors warranting consideration even with negative IGRA include:
- Previous TB exposure
- Residence/travel in TB-endemic areas
- Underlying conditions predisposing to infection
- Chronic lung disease
- Alcohol abuse, smoking
- Living with people with TB 4, 1
Consultation with a TB specialist is recommended to determine appropriate therapy for individual patients 1.
Critical Drug Interaction
Important caveat: Rifampicin (commonly used for latent TB treatment) increases hepatic metabolism of upadacitinib, requiring consideration of dose increase during concurrent therapy 3. Coordinate with infectious disease specialists when managing this interaction.
Ongoing Monitoring
- Monitor for TB signs/symptoms during upadacitinib treatment, even in patients who tested negative for latent TB prior to therapy 1
- Higher vigilance needed in endemic regions where TB risk remains elevated throughout treatment 2
The evidence is clear and consistent across FDA labeling, international guidelines, and recent research: latent TB treatment is mandatory before upadacitinib initiation in IGRA-positive patients to prevent potentially fatal TB reactivation.